Stocktoria
Marker Therapeutics, Inc. MRKR
Marker Therapeutics, Inc. (MRKR) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $3.5M at a -343.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MRKR | Marker Therapeutics, Inc. | 2/9 | — | — | — |
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
| CRVO | CervoMed Inc. | 1/9 | -12.9 | — | — |
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
| ATAI | AtaiBeckley Inc. | 4/9 | — | — | — |
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | 4/9 | -3.85 | — | — |
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
FAQ
Is MRKR financially healthy?
Marker Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does MRKR pay a dividend?
No, Marker Therapeutics, Inc. does not currently pay a dividend.
How profitable is MRKR?
In FY2025, Marker Therapeutics, Inc. had a net margin of -343.0% and a return on equity of -72.4%.
What is the analyst price target for MRKR?
The average Wall-Street price target for Marker Therapeutics, Inc. is $7.87, about 578.2% above the recent price, from 3 analysts.
Is MRKR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Marker Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.